EV Biologics Corp., a Wyoming-based biotechnology company, has engaged Foley to facilitate the propriety development of its exosome technology and technical innovation.
In its announcement, the company cited Foley’s standing at the top of intellectual property law in biotechnology and organics and its specialty in stem cell and extracellular vesicle technology.
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer.
Related News
03 February 2025
Press Releases
Foley Announces 2025 New Partner Class
Foley & Lardner LLP is pleased to announce the promotion of 17 lawyers to the firm’s partnership, effective February 1, 2025.
17 January 2025
Press Releases
Young Leaders Share Their Dreams for the Future at Foley’s Annual MLK Jr. Oratory Competition
The voices of tomorrow resonated with hope and inspiration today as elementary students from Dallas, Houston, and Chicago took the stage for the final rounds of Foley & Lardner LLP’s Annual MLK Jr. Oratory Competitions.
17 January 2025
Press Releases
Foley Represents Hospice Coalition in Lawsuit Against CMS Special Focus Program
Foley & Lardner LLP is representing a multi-state coalition of hospices and hospice associations in challenging the Centers for Medicare & Medicaid Services’ Hospice Special Focus Program (SFP) Final Rule and List.